A Prospective Study on Dietary Acrylamide Intake and the Risk for Breast, Endometrial, and Ovarian Cancers

Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.
Cancer Epidemiology Biomarkers & Prevention (Impact Factor: 4.13). 10/2010; 19(10):2503-15. DOI: 10.1158/1055-9965.EPI-10-0391
Source: PubMed


Acrylamide is a probable human carcinogen formed during cooking of many common foods. Epidemiologic studies on acrylamide and breast cancer risk have been null; however, positive associations with ovarian and endometrial cancers have been reported. We studied acrylamide intake and risk for breast, endometrial, and ovarian cancers in a prospective cohort study.
We assessed acrylamide intake among 88,672 women in the Nurses' Health Study using food frequency questionnaires administered every 4 years. Between 1980 and 2006, we identified 6,301 cases of invasive breast cancer, 484 cases of invasive endometrial adenocarcinoma, and 416 cases of epithelial ovarian cancer. We used Cox proportional hazards models to study the association between acrylamide and cancer risk.
We found no association between acrylamide intake and breast cancer overall or according to estrogen and progesterone receptor status. We found an increased risk for endometrial cancer among high acrylamide consumers (adjusted relative risk for highest versus lowest quintile = 1.41; 95% CI, 1.01-1.97; P for trend = 0.03). We observed a nonsignificant suggestion of increased risk for ovarian cancer overall (relative risk, 1.25; 95% CI, 0.88-1.77; P trend = 0.12), with a significantly increased risk for serous tumors (relative risk, 1.58; 95% CI, 0.99-2.52; P trend = 0.04). Associations did not differ by smoking status.
We observed no association between acrylamide and breast cancer. Risk for endometrial cancer and possibly ovarian cancer was greater among high acrylamide consumers.
This is the second prospective study to report positive associations with endometrial and ovarian cancers. These associations should be further evaluated to inform public health policy.

Download full-text


Available from: Kathryn M Wilson,
  • Source
    • "In rats, tumorigenesis occurs in several hormonally regulated tissues [2] [3] . Some previous studies showed that ACR is capable of inducing genotoxic, carcinogenic, developmental, and reproductive effects in tested animals. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To assesses the effects of long term exposure to low dose of acrylamide (0.4 mg/g) in post-weaning Sprague–Dawley rats on the structure of the reproductive organ as well as DNA integrity. Methods: The histological changes in the male and female reproductive organs the morphological changes in sperms as well as the genotoxic effect of acrylamide were assessed. The effect acrylamide on pregnancy outcome was evaluated. Results: Testes of acrylamide-fed rats showed decreased number of seminiferous tubules containing mature sperms and degenerative changes in sperm germ cell layers. Some sperms of epididymal cauda showed head deformity. In female, acrylamide included cystic ovarian changes, degenerative changes of zona pelluida, granulosa cells and oocytes. Post implantation loss and decrease in the number of full term fetuses were detected. Resorption sites showed necrotic fetal tissue with vacuolation of amniotic cells. Conclusion: Acrylamide cause harmful effect on the reproductive organ structure, fertility and cause extensive DNA damage in peripheral blood lymphocytes.
  • Source
    • "The overall sample size of this meta-analysis was relatively large, and all the cohorts provided separate RRs among all women as well as neversmoking women. Although each study attempted to adjust NOTE: Weights are from random effects analysis Overall (I-squared = 0.0%, p = 0.547) Larsson et al, 2009 Wilson et al, 2010 ID Obon-Santacana, 2014 Hogervorst et al, 2007 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Acrylamide has been associated with carcinogenicity in experimental animals, but potential health risks of dietary acrylamide intake and endometrial cancer in human are inconclusive. Thus, a meta-analysis of prospective cohort studies was conducted to provide a quantitative assessment of the association between dietary acrylamide intake and endometrial cancer risk. Methods: PubMed database was used to identify prospective cohort studies on dietary acrylamide intake and endometrial cancer risk published up to June 2014. Since smoking is an important source of acrylamide and is inversely associated with endometrial cancer risk, the association was examined in women who never smoked as well. Multivariable relative risks (RR) adjusting for potential confounders were combined using random effects models. Results: Four large prospective cohort studies were identified, which included 453,355 female participants and 2,019 endometrial cancer cases. There was no association between dietary acrylamide intake and endometrial cancer risk overall [pooled RR for high vs. low intake = 1.10; 95% confidence interval (CI) 0.91-1.34]. High acrylamide intake, however, was significantly associated with increased risk of endometrial cancer among women who never smoked (pooled RR for high vs. low intake = 1.39; 95% CI 1.09-1.77). In dose-response analyses, pooled RRs for an increase of 10 µg/day were 1.04 (95% CI 0.97-1.11) among all women and 1.11 (95% CI 1.04-1.19) among never-smoking women. Conclusions: Endometrial cancer risk was not associated with dietary acrylamide intake overall. Among women who never smoked, however, there was a significantly increased endometrial cancer risk in women who consumed high dietary acrylamide.
    Archives of Gynecology and Obstetrics 12/2014; 291(6). DOI:10.1007/s00404-014-3595-8 · 1.36 Impact Factor
  • Source
    • "Acrylamide intake and endometrial cancer risk between acrylamide intake and EC risk, especially in never smokers (Hogervorst et al, 2007). Likewise, the Nurses' Health Study (NHS) reported an increased relative risk among women with the highest acrylamide intake (Wilson et al, 2010); however, no associations between acrylamide intake and EC were observed in the Swedish Mammography Cohort (SMC; Larsson et al, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Three prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The objective of this study was to evaluate the association between acrylamide intake and EC risk: for overall EC, for type-I EC, and in never smokers and never users of oral contraceptives (OCs). Smoking is a source of acrylamide, and OC use is a protective factor for EC risk. Methods: Cox regression was used to estimate hazard ratios (HRs) for the association between acrylamide intake and EC risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Acrylamide intake was estimated from the EU acrylamide monitoring database, which was matched with EPIC questionnaire-based food consumption data. Acrylamide intake was energy adjusted using the residual method. Results: No associations were observed between acrylamide intake and overall EC (n=1382) or type-I EC risk (n=627). We observed increasing relative risks for type-I EC with increasing acrylamide intake among women who both never smoked and were non-users of OCs (HRQ5vsQ1: 1.97, 95% CI: 1.08-3.62; likelihood ratio test (LRT) P-value: 0.01, n=203). Conclusions: Dietary intake of acrylamide was not associated with overall or type-I EC risk; however, positive associations with type I were observed in women who were both non-users of OCs and never smokers.
    British Journal of Cancer 06/2014; 111(5). DOI:10.1038/bjc.2014.328 · 4.84 Impact Factor
Show more